New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 6, 2014
08:41 EDTBCLIBrainStorm Cell announces first patient enrollment in Phase II ALS trial
BrainStorm Cell announced that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital. BrainStorm's Phase II trial is a randomized, double-blind, placebo controlled multi-center study designed to evaluate the safety and efficacy of transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors in 48 ALS patients. The trial is also being conducted at the University of Massachusetts Memorial Hospital and the Mayo Clinic in Rochester, Minnesota.
News For BCLI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
06:48 EDTBCLIBrainStorm receives $1.1M from Israel's OCS
BrainStorm Cell Therapeutics announced today that wholly-owned subsidiary Brainstorm Cell Therapeutics was awarded a grant of approximately $1.1M from Israel's Office of the Chief Scientist, or OCS. This is the eighth year that BrainStorm has been in receipt of grant support from the Office of the Chief Scientist, which is part of the Ministry of Trade and Industry Program to support innovative technologies in Israel. The funds will support the development NurOwn, BrainStorm's innovative mesenchymal stem cell-based platform for treating neurodegenerative diseases including BrainStorm's phase 2 clinical program in amyotrophic lateral sclerosis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use